Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis (Q45525964)

14 December 2017

Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis (English)

1 reference

cost-effectiveness analysis

14 December 2017

0 references

0 references

1 reference

1 reference

hepatocellular carcinoma

1 reference

1 reference

2

Norah A Terrault

1 reference

14 December 2017

Derek Patel

1

1 reference

14 December 2017

Francis Y Yao

series ordinal

3

1 reference

14 December 2017

Nathan M Bass

series ordinal

4

1 reference

14 December 2017

Uri Ladabaum

series ordinal

5

1 reference

14 December 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Clinical Gastroenterology and Hepatology

14 December 2017

1 reference

14 December 2017

3

1 reference

14 December 2017

1

1 reference

14 December 2017

75-84

1 reference

Epidemiology of primary liver cancer

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Hepatitis C virus and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Treatment of hepatocellular carcinoma associated with cirrhosis in the era of liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Right lobe living donor liver transplantation: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Living donor liver transplantation for early hepatocellular carcinoma: A life-expectancy and cost-effectiveness perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Living-donor versus cadaveric liver transplantation for non-resectable small hepatocellular carcinoma and compensated cirrhosis: a decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Outcome of 67 patients with hepatocellular cancer detected during screening of 1125 patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience).

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Prognostic prediction and treatment strategy in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Survival and prognostic indicators in compensated and decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Compensated cirrhosis: Natural history and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Prognostic Value of Child-Turcotte Criteria in Medically Treated Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Efficacy of a surveillance program for early detection of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis in 206 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Prognosis of hepatocellular carcinoma: the BCLC staging classification

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Resection of hepatocellular carcinomas. Results in 72 European patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Comparison of resection, liver transplantation and transcatheter oily chemoembolization in the treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

A survey of liver transplantation from living adult donors in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Adult living donor liver transplantation: the hepatologist's perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Long-term results of living-related donor liver graft transplantation: a single-center analysis of 110 transplants

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Right lobe living donor liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Adult-to-Adult Living Donor Liver Transplantation Using Extended Right Lobe Grafts

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Screening methods for early detection of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Accuracy of radiology in detection of hepatocellular carcinoma before liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Detection of hepatocellular carcinoma in cirrhotic patients: sensitivity of CT and ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Malignancies in patients with cirrhosis: CT sensitivity and specificity in 200 consecutive transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Cost-effectiveness of cadaveric and living-donor liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Lack of relationship between preoperative measures of the severity of cirrhosis and short-term survival after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Liver allocation for HCC: a moving target

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Liver transplantation for hepatocellular carcinoma: the MELD impact.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Diagnosis and screening of small hepatocellular carcinomas. Comparison of radionuclide imaging, ultrasound, computed tomography, hepatic angiography, and alpha 1-fetoprotein assay

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

The diagnosis of small hepatocellular carcinomas: efficacy of various imaging procedures in 100 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Detecting hepatocellular carcinoma: value of unenhanced or arterial phase CT imaging or both used in conjunction with conventional portal venous phase contrast-enhanced CT imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Gains in life expectancy from medical interventions--standardizing data on outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Five-hundred life-saving interventions and their cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900443-4

7 January 2021

10.1016/S1542-3565(04)00443-4

Identifiers

DOI

1 reference

14 December 2017

1 reference